BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang X, Tan J, Wang Y, Chen J, Li J, Jiang Z, Quan Y, Jin J, Li Y, Cen S, Li Y, Peng Z, Li Z. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action. J Med Chem 2020;63:5972-89. [PMID: 32378892 DOI: 10.1021/acs.jmedchem.0c00232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Ye X, Qiu R, He X, Hu Z, Zheng F, Huang X, Xie X, Chen F, Ou H, Lin G. miR-647 inhibits hepatocellular carcinoma cell progression by targeting protein tyrosine phosphatase receptor type F. Bioengineered 2022;13:1090-102. [PMID: 34969357 DOI: 10.1080/21655979.2021.2017628] [Reference Citation Analysis]
2 Groaz E, De Clercq E, Herdewijn P. Anno 2021: Which antivirals for the coming decade? Annu Rep Med Chem 2021;57:49-107. [PMID: 34744210 DOI: 10.1016/bs.armc.2021.09.004] [Reference Citation Analysis]
3 Martinez MA, Franco S. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection. Adv Exp Med Biol 2021;1322:139-57. [PMID: 34258740 DOI: 10.1007/978-981-16-0267-2_6] [Reference Citation Analysis]
4 Martinez MA, Franco S. Therapy Implications of Hepatitis C Virus Genetic Diversity. Viruses 2020;13:E41. [PMID: 33383891 DOI: 10.3390/v13010041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang Y, Li J, Tan J, Yang B, Quan Y, Peng Z, Li Y, Li Z. Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors. J Med Chem 2022. [PMID: 35050619 DOI: 10.1021/acs.jmedchem.1c01637] [Reference Citation Analysis]